PENG Qin, TANG Shao-hui *, SHI Heng
|
|
- Mary Terry
- 5 years ago
- Views:
Transcription
1 Meta [ ] (CHC) PubMed EMBASE The Cochrane Central Register of Controlled Trials CNKI CHC (RCTs) RevMan 5.3 Meta 6 RCT 1100 Meta(RVR) (cevr) (SVR 24 ) (P ) (60mg/d) RVR cevr SVR 24 (P ) (10mg/d) RVR cevr (P 0.05) SVR 24 (P=0.65) (P 0.05) CHC 60mg/d CHC 10mg/d [ ] Meta [ ] R [ ] A [ ] (2016) [DOI] /j.issn PENG Qin, TANG Shao-hui *, SHI Heng Department of Gastroenterology, First Affiliated Hospital of Jinan University, Guangzhou , China * Corresponding author, tangshaohui205@163.com [Abstract] Objective To evaluate the efficacy and safety of daclatasvir in treatment of chronic hepatitis C (CHC). Methods Articles regarding treatment and safety of CHC were retrieved from PubMed, EMBASE, The Cochrane Central Register of Controlled Trials, Chinese Journals Full-text Database (CNKI, China National Knowledge Infrastructure), and WanFang Digital Journal Full-text Database to collect clinical RCTs (randomized controlled trials) for CHC treated by daclatasvir. Meta-analysis was performed by using Review Manager 5.3. Results A total of six RCTs including 1100 patients met the inclusion criteria. Metaanalysis results were as follows. 1) The overall RVR (rapid virological response), cevr (complete early virological response) and SVR 24 (sustained virological response at post-treatment week 24) rates were significantly higher in daclatasvir group than in control group. 2) The RVR, cevr, and SVR 24 rates were significantly higher in daclatasvir (60mg/d) group than in control group. 3) The RVR and cevr rates were significantly higher in daclatasvir (10mg/d) group than in control group, but no significant difference existedbetweenthetwogroupsinthesvr 24 rate. 4) No significant differences were found in nonspecific adverse events, liver function, hematologic system or skin between daclatasvir and control groups. Conclusion Daclatasviriseffectiveandsafein treatment of CHC, and daclatasvir 60mg/d is a better choice as compared with daclatasvir 10mg/d. [Key words] hepatitis C, chronic; daclatasvir; randomized controlled trials; Meta-analysis 1.7 (hepatitis C virus HCV) [1] 15% HCV (CHC) 20% CHC 5%~7% [2] CHC [ ] [ ] ( ) [ ] tangshaohui205@163.com HCV [3-4] NS3/4A NS5A NS5B NS3 [5] (daclatasvir DCV) HCV NS5A [5] 2011 Nettles [6] CHC CHC
2 Med J Chin PLA, Vol. 41, No. 6, June 1, PubMed EMBASE The Cochrane Central Register of Controlled Trials CNKI daclatasvir randomized controlled trial chronic hepatitis C 1.2 RCT 18~70 >6 -HCV HCV-RNA 105U/ml ALT> 2 CHC Jadad 3 RCT Jadad <3 RCT 1.3 ( ) ( HCV-RNA ) ( ) 1.4 Jadad [7] ( ) 1 3 <3 1.5 Review Manager 5.3 Meta I 2 50% P 0.05 I 2 50% P 0.05 [8] (relative risk RR) 95% (confidence interval CI) P< (funnel plot) [9-14] ( 1) Ratziu [14] [9-13] 681 ( 1) 2.2 Jadad 4~5 ( 2) Literature databases: PUBMED, COCHRANE, EMBASE, WANFANG and CNKI Search fields: Title, abstract, key words Years: All years Limits: Randomized controlled trial Searching strings: (daclatasvir); (BMS ) AND (HCV); (hepatitis C); (hepatitis C virus); (HCV infection) Total number of unique hits: n=147 Article selected based on titles Included: n=12 Excluded: n=135 Reason: Relevant information not reported irrelevant study topic Article selected based on full papers Included: n=6 Excluded: n=6 Reason: Relevant information not reported Total=6 1 Meta Fig.1 Search strategy of information related to meta-analysis
3 Trial Hézode, et al [9] 2015 (n=395) Dore, et al [10] 2015 (n=151) Suzuki, et al [11] 2014 (n=45) Izumi, et al [12] 2014 (n=42) Pol, et al [13] 2012 (n=48) Median age (range) Gender (male,%) 1 Tab.1 Basic data of the included studies HCV-RNA (median, log10) Genotype Type of treatment and dose Treatment duration (week) RVR cevr SVR 24 51(22-70) G1a,275/395 D(20mg/d)+P(180 g/w)+r( g/d) 24 91/ /159 95/159 50(18-67) G1b,88/395 D(60mg/d)+P(180 g/w)+r( g/d) 24 87/ /158 99/158 51(25-66) G4,31/395 PBO+P(180 g/w)+r( g/d) 24 11/78 34/78 30/78 52(28-64) D(60mg/d)+P(180 g/w)+r(0.8g/d) 12 43/50 43/50 38/50 52(25-67) G2,71/151 G3,80/151 D(60mg/d)+P(180 g/w)+r(0.8g/d) 16 35/50 43/50 37/50 55(20-63) PBO+P(180 g/w)+r(0.8g/d) 24 20/51 34/51 31/51 51(21-68) D(10mg/d)+P( g/w)+r(0.6-1g/d) 24/48 12/18 12/18 8/18 55(36-70) G1(G1a+G1b), 45/45 D(60mg/d)+P( g/w)+r(0.6-1g/d) 24/48 11/19 15/19 12/19 50(42-66) PBO+P( g/w)+r(0.6-1g/d) 48 0/8 5/8 5/8 56(26-68) D(10mg/d)+P(180 g/w)+r(0.6-1g/d) 24 12/17 15/17 12/17 57(31-67) G1(G1a+G1b), 42/42 D(60mg/d)+P(180 g/w)+r(0.6-1g/d) 24 13/17 16/17 15/17 54(41-65) PBO+P(180 g/w)+r(0.6-1g/d) 24 1/8 5/8 6/8 52(38-66) D(3mg/d)+P(180 g/w)+r( g/d) 12 5/12 7/12 5/12 51(37-68) G1a,32/48 D(10mg/d)+P(180 g/w)+r( g/d) 12 11/12 10/12 10/12 51(43-67) G1b,16/48 D(60mg/d)+P(180 g/w)+r( g/d) 12 10/12 10/12 10/12 50(28-67) PBO+P(180 g/w)+r( g/d) 12 1/12 5/12 3/12 D(20mg/d)+P/R 12 47/203 71/203 Ratziu, et al [14] 2012 (n=419) D(60mg/d)+P/R 12 53/199 83/199 PBO+P/R 12 0/17 0/17 Median age, gender, HCV-RNA, treatment duration, RVR, cevr and SVR 24 is respectively divided into different groups according to the type of treatment and dose; Genotype is divided into different groups according to G1a, G1b, G2, G3 and G4. D. Daclatasvir; P. Pegylated interferon- ; R. Ribavirin; PBO. Placebo; RVR. Rapid virological response; cevr. Complete early virological response; SVR 24. Sustained virological response at posttreatment week 24 2 Jadad Tab.2 Jadad scores of the included clinical trials Trial Randomization Double-blinding Withdraw and drop out Jadad score Hézode, et al [9] /2015 Dore, et al [10] /2015 Suzuki, et al [11] /2014 Izumi, et al [12] /2014 Pol, et al [13] /2012 Ratziu, et al [14] /2012 and it was appropriate(2) and it was appropriate(2) and it was appropriate(2) and it was appropriate(2) but not described(1) but not described(1) (RVR) 4 HCV-RNA 2 log [15] 6 RCT [9-14] ( ) 4 HCV-RNA 6 (P=0.05) Meta RVR (46.44%) (18.97% RR= %CI 1.95~7.28 P ) mg/d (60mg/d) 4 HCV-RNA 6 (P=0.06) Meta (60mg/d) RVR (49.90%) (18.97% RR= %CI 2.35~4.35 P ) mg/d (10mg/d) 4 HCV-RNA 3 [11-13] (P=0.85) Meta (10mg/d) RVR (74.47%)
4 Med J Chin PLA, Vol. 41, No. 6, June 1, CHC (RVR) Meta Fig.2 Forest plot of RVR rate of DCV+P/R and PBO+P/R for CHC 3 (60mg/d) CHC (RVR) Meta Fig.3 Forest plot of RVR rate of DCV(60mg/d)+P/R and PBO+P/R for CHC (7.14% RR= %CI 2.67~28.95 P= ) (cevr) 12 HCV-RNA [15] 6 RCT [9-14] ( ) 12 HCV-RNA 6 (P=0.10) Meta cevr (61.56%) (47.70% RR= %CI 1.39~1.92 P ) 4 (10mg/d) CHC (RVR) Meta Fig.4 Forest plot of RVR rate of DCV(10mg/d)+P/R and PBO+P/R for CHC 5 CHC (cevr) Meta Fig.5 Forest plot of cevr rate of DCV+P/R and PBO+P/R for CHC (60mg/d) (60mg/d) 12 HCV-RNA 6 (P=0.10) Meta (60mg/d) cevr (65.74%) (47.70% RR= %CI 1.40~1.94
5 P ) (10mg/d) (10mg/d) 12 HCV-RNA 3 [11-13] (P=0.43) Meta (10mg/d) cevr (78.72%) (53.57% RR= %CI 1.00~2.07 P=0.05 7) (SVR 24 ) 24 HCV-RNA [15] 5 RCT [9-13] ( ) 24 HCV-RNA 5 (P=0.11) Meta SVR 24 (65.08%) (47.77% RR= %CI 1.18~1.68 P= ) (60mg/d) (60mg/d) 24 HCV-RNA 5 (P=0.15) Meta (60mg/d) SVR 24 (68.95%) (47.77% RR= %CI 1.20~1.71 P ) (10mg/d) (10mg/d) 24 HCV-RNA 6 (60mg/d) CHC (cevr) Meta Fig.6 Forest plot of cevr rate of DCV(60mg/d) +P/R and PBO+P/R for CHC 7 (10mg/d) CHC (cevr) Meta Fig.7 Forest plot of cevr rate of DCV(10mg/d)+P/R and PBO+P/R for CHC 8 CHC (SVR) Meta Fig.8 Forest plot of SVR rate of DCV+P/R and PBO+P/R for CHC 9 (60mg/d) CHC (SVR) Meta Fig.9 Forest plot of SVR rate of DCV(60mg/d)+P/R and PBO+P/R for CHC
6 Med J Chin PLA, Vol. 41, No. 6, June 1, [9-11] (P=0.03) Meta (10mg/d) SVR 24 (P= ) 10 (10mg/d) CHC (SVR) Meta Fig.10 Forest plot of SVR rate of DCV(10mg/d)+P/R and PBO+P/R for CHC [9,11-13] Meta ( ) (P ) (RR= %CI 0.32~0.52 P ) (RR= %CI 0.44~1.01 P=0.05 3) [9-12] (ALT) (TBil) Meta (P ) [9-13] ( ) Meta (P ) [9-13] Meta (P ) 2.4 RR Suzuki [9] RR Dore [10] RR (logrr) ( 11) 3 Tab.3 Adverse events of the included studies Category Concrete forms Events/Total (incidence rate, %) DCV+P/R PBO+P/R RR, 95%CI(P values) Fatigue 211/424(49.76) 62/106(58.49) 0.86[0.72,1.03](P=0.11) Headache 184/424(43.40) 48/106(45.28) 0.96[0.76,1.21](P=0.73) Insomnia 132/424(31.13) 36/106(33.96) 0.86[0.64,1.14](P=0.29) Nonspecific AEs Nausea 126/390(32.31) 29/98(29.59) 0.79[0.37,1.68](P=0.53) Diarrhea 90/388(23.20) 54/94(57.45) 0.41[0.32,0.52](P ) Decreased appetite 104/424(24.53) 26/106(24.53) 0.99[0.69,1.44](P=0.98) Cough 72/387(18.60) 53/98(54.08) 0.66[0.18,2.37](P=0.52) Arthralgia 66/388(17.01) 24/94(25.53) 0.67[0.44,1.01](P=0.05) Liver dysfunction Elevated ALT 9/488(1.84) 1/145(0.69) 1.51[0.34,6.68](P=0.59) Elevated bilirubin 4/488(0.82) 1/145(0.69) 0.87[0.19,4.07](P=0.86) Anemia 45/524(8.59) 14/157(8.92) 0.90[0.53,1.54](P=0.70) Hematologic abnormalities Thrombocytopenia 12/488(2.46) 6/145(4.14) 0.62[0.24,1.65](P=0.34) Neutropenia 139/524(26.53) 46/157(29.30) 0.87[0.65,1.15](P=0.32) Rash 147/524(28.05) 46/157(29.30) 0.93[0.71,1.23](P=0.63) Skin abnormalities Pruritus 179/524(34.16) 49/157(31.21) 1.06[0.81,1.38](P=0.67) Alopecia 116/424(27.36) 23/106(21.70) 1.06[0.50,2.24](P=0.88) DCV. Daclatasvir; P. Pegylated interferon- ; R.Ribavirin;PBO.Placebo
7 SE(log[RR]) RR Fig.11 Funnel plot of the included studies 3 CHC [16] [17] HCV 1 CHC NS3/4A ( ) NS5A ( ) NS5B ( ) NS3 ( ) [16] 2014 [18] (Peg IFN)/ RBV (telaprevir TVR) (boceprevir BOC) 1 TVR BOC (1 /8h) ( ) [19] (daclatasvir DCV) TVR BOC CHC DCV HCV NS5A DCV NS3 DCV NS5A NS5A [20-22] DCV ( 1 ) 1-4 [23] [9-14] Peg IFN/RBV CHC Meta CHC ( Jadad 3 ) Meta RVR cevr SVR 24 (60mg/d) RVR cevr SVR 24 (10mg/d) RVR cevr SVR 24 ( ) CHC ( 6 RCTs 1100 ) (12~48 ) CHC [1] Gower E, Estes C, Blach S,et al. Global epidemiology and genotype distribution of the hepatitis C virus infection[ J]. J Hepatol, 2014, 61(1 Suppl): S45-S57. [2] Chen PY, Ma AX. Meta-analysis of the effectiveness on peginterferon for chronic hepatitis C[ J]. J Evid Based Med, 2014, 31(6): [,. Meta [J]., 2014, 31(6): ] [3] Ma LY, Zhang P, Chen Q, et al. Changes in number of peripheral blood cells in patients with chronic hepatitis C after treated with interferon alpha 2b combined with ribavirin and their clinical significances[ J]. J Jilin Univ (Med Ed), 2015, 41(3): [,,,. -2b [J]. ( ), 2015, 41(3): ] [4] Ma YH, Zhou LH. Clinical observation of patients with chronic hepatitis C and diabetes mellitus treated by PEG-interferon and ribavirin[ J]. J Logist Univ PAPF (Med Sci), 2013, 22(3): [,. [J]. ( ), 2013, 22(3): ] [5] Wan JL, He X, Bai M. Research progress on combination therapeutic regimen of direct anti HCV agents[ J]. Drug Clin, 2014, 29(4): [,,. [J]., 2014, 29(4): ] [6] NettelsRE,GaoM,BifanoM,et al. Multiple ascending dose study of BMS , a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus
8 Med J Chin PLA, Vol. 41, No. 6, June 1, genotype 1[ J]. Hepatology, 2011, 54(6): [7] JadadAR,MooreRA,CarrollD,et al. Assessing the quality of reports of randomized clinical trails: is blinding necessary?[ J]. Control Clin Trials, 1996, 17(1): [8] Tian JH, Li L, Zhao Y, et al. Writing and reporting of network meta-analysis[ J]. Chin J Drug Evaluation, 2013, 30(6): , 333. [,,,. Meta [J]., 2013, 30(6): , 333.] [9] Hézode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study[ J]. Gut, 2015, 64(6): [10] Dore G J, L aw itz E, Hézode C, et al. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection[ J]. Gastroenterology, 2015, 148(2): [11] Suzuki F, Toyota J, Ikeda K, et al. A randomized trial of daclatasivir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection[ J]. Antivir Ther, 2014, 19(5): [12] Izumi N, Yokosuka O, Kawada N, et al. Daclatasivir combined with peginterferon alfa-2b and ribavirin in Japanese patient infected with hepatitis C genotype 1[ J]. Antivir Ther, 2014, 19(5): [13] Pol S, Ghali RH, Rustgi VK, et al. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial[ J]. Lancet Infect Dis, 2012, 12(9): [14] Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir (DCV; BMS ), peginterferon alfa/2a and ribaviron in HCV-infected prior null and partial responders: 12 week results of phase 2b command-2 trial[ J]. J Hepatol, 2012, 56(Suppl 2): [15] LI GY. Efficiency of different peginterferons and ribaviron for the treatment of chronic hepatitis C[ J]. Anti Infect Pharm, 2014, 11(5): [. [J]., 2014, 11(5): ] [16] Yang XY, Wang JX. Advance in research of anti-hcv drugs and therapies[ J]. Chin J New Drug, 2014, 23(22): [,. [J]., 2014, 23(22): ] [17] Zhou YM, Dou XG, Zhang L. Research progress of hepatitis C virus genotyping[ J]. Chin J Pract Intern Med, 2014, 34(8): [,,. [J]., 2014, 34(8): ] [18] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection[ J]. J Hepatol, 2014, 60(1): [19] WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the screening, care and treatment of persons with hepatitis C infection[m]. Geneva: World Health Organization, [20] Fridell RA, Qiu D, Valera L, et al. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS [ J]. J Virol, 2011, 85(14): [21] Qiu D, Lemm JA, O'Boyle DR II, et al. The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization[ J]. J Gen Virol, 2011, 92(Pt 11): [22] Lee C, Ma H, Hang JQ, et al. The hepatitis C virus NS5A inhibitor (BMS ) alters the subcellular localization of the NS5A non-structural viral protein[ J]. Virology, 2011, 414(1): [23] Wang C, Jia L, Huang H, et al. In vitro activity of BMS on hepatitis C virus genotype 4 NS5A[ J]. Antimicrob Agents Chemother, 2012, 56(3): ( ) ( )
Daclatasvir combined with peginterferon α and ribavirin for the treatment of chronic hepatitis C: a meta analysis
DOI 10.1186/s40064-016-3218-x REVIEW Open Access Daclatasvir combined with peginterferon α and ribavirin for the treatment of chronic hepatitis C: a meta analysis Qin Peng 1, Kang Li 2, Ming Rong Cao 3,
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationOriginal article Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1
Antiviral Therapy 2014; 19:501 510 (doi: 10.3851/IMP2731) Original article Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1 Namiki
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationSYNOPSIS Final Clinical Study Report for Study AI444031
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Name of Active Ingredient: () Individual Study Table Referring to the Dossier (For National Authority Use Only) SYNOPSIS for Study
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationNew Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationTreatment with the New Direct Acting Antivirals for Hepatitis C
Treatment with the New Direct Acting Antivirals for Hepatitis C Mary Olson, DNP, ANP-BC Clinical Trials Program Director Weill Cornell Medical College The Center for the Study of Hepatitis C Objectives
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationFrom 19 February 2015
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment pharmaceuticals with new active ingredients, in accordance
More informationSVR Updates from the 2013 EASL
Updates from the 2013 EASL By Tracy Swan, Treatment Action Group Streamlining HCV Treatment Treatment for hepatitis C virus (HCV) is becoming simpler, shorter, and more effective. All-oral combinations
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More informationTITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update
TITLE: Re-treatment with Direct Acting Antivirals for Chronic Hepatitis C Genotype 1: Emerging Evidence of Clinical Effectiveness and Safety An Update DATE: 02 January 2015 RESEARCH QUESTION What is the
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationGeneral Statement for Drugs for the Treatment of Hepatitis C
General Statement for Drugs for the Treatment of Hepatitis C Use the following criteria to determine patient eligibility for subsidisation under the PBS for hepatitis C treating agents. By writing a PBS
More informationShould Elderly CHC Patients (>70 years old) be Treated?
Should Elderly CHC Patients (>70 years old) be Treated? Deepak Amarapurkar Consultant Gastroenterologist & Hepatologist Bombay Hospital & Medical Research Center, Mumbai & Jagjivanram Western Railway Hospital,
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationCASE STUDY. Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be?
Adverse Events in treatment chronic hepatitis C patients with PegInterferon and Ribavirin What would your management decision be? CASE STUDY Pham Thi Thu Thuy MD, PhD Ho Chi Minh City Vietnam Serious Adverse
More informationGlecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1
Phase 3 Treatment-Naïve and Treatment-Experienced Glecaprevir-Pibrentasvir in Cirrhotic Genotype 1, 2, 4, 5, and 6 EXPEDITION-1 EXPEDITION-1: Study Features EXPEDITION-1 Trial Design: Open-label, single-arm,
More informationAbbreviated Class Update: Hepatitis C
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTreatment of chronic hepatitis C virus infection in the near future
EDITORIAL Treatment of chronic hepatitis c virus infection in the near future., 2013; 12 (6): 00-00 November-December, Vol. 12 No. 6, 2013: 00-00 1 Treatment of chronic hepatitis C virus infection in the
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationPEARL-I. Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4. Treatment Naïve and Treatment Experienced
Phase 2b Treatment Naïve and Treatment Experienced Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I Hézode C, et al. Lancet. 2015 March 30. [Epub ahead of print] PEARL-I: Study Design
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationDevelopments in the Treatment of Hepatitis C: A New Era
Developments in the Treatment of Hepatitis C: A New Era Nancy Love, PharmD, BCPS Memorial Medical Center, Johnstown, PA October 17, 2014 Pharmacist Objectives Summarize the results of clinical trials for
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationAbstract 233. Post-treatment follow up. Pawlotsky JM, et al. 63rd AASLD; Boston, MA; November 9-13, 2012:. Abst ALV loading* RVR at W4
Jean-Michel Pawlotsky, Shiv K. Sarin, Graham R. Foster, Cheng-Yuan Peng, Jens Rasenack, Robert Flisiak, Teerha Piratvisuth, Heiner Wedemeyer, Wan-Long Chuang, Wei Zhang and Nikolai V. Naoumov Abstract
More informationRecent Management of Chronic Hepatitis C
2014-6-12 KASL Liver Week 2014 Recent Management of Chronic Hepatitis C Jae-Jun Shim Kyung Hee University School of Medicine, Seoul, Korea Meeting today Cost and future perspectives Guidelines Recent guidelines
More informationThe Liver Meeting 2013: The 64th Annual Meeting of the AASLD Washington, DC, November 1 5, 2013 Presentation LB-1
Phase 2b Study of the Interferon-Free and Ribavirin-Free Combination of Daclatasvir, Asunaprevir, and BMS-791325 for 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 1 Infection Everson GT,
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationTransformation of Chronic Hepatitis C Treatment
Transformation of Chronic Hepatitis C Treatment UVHS, Adana, 22 May 2015 Christoph Sarrazin Goethe-University Hospital Frankfurt am Main Germany Epidemiology of HCV Infection Global Global HCV Prevalence
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationHarvoni: solution to HCV
Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationNew Treatments for Chronic Hepatitis C. Rafael Esteban Hospital Valle Hebron. Barcelona Spain
New Treatments for Chronic Hepatitis C Rafael Esteban Hospital Valle Hebron. Barcelona Spain The present: a complex treatment with a better SVR Genotype 1 Genotypes 2 and 3 Triple therapy Boceprevir (BOC)
More informationPegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience
Pegylated Interferon Alfa-2b (Peg-Intron) Plus Ribavirin (Rebetol)in the Treatment of Chronic Hepatitis C: A Local Experience E L Seow, PH Robert Ding Island Hospital, Penang, Malaysia. Introduction Hepatitis
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationDr. Siddharth Srivastava
Dr. Siddharth Srivastava MD, DM (Gastroenterology) Associate Professor GIPMER, New Delhi Rashtriya Gaurav Award 2013 for work on hepatitis B and C Set up Liver clinic at GIPMER and in charge EUS laboratory.
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationInfection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
More informationENABLE 1 Study. To evaluate the safety and tolerability of eltrombopag Primary efficacy outcome: proportion of patients who achieve SVR
Final Results of ENABLE 1, a Phase 3, Multicenter Study of as an Adjunct for Antiviral Treatment of Hepatitis C Virus -Related Chronic Liver Disease Associated With Thrombocytopenia N. Afdhal; G. Dusheiko;
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationBest of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS
Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals
More informationUpdate on chronic hepatitis C treatment: current trends, new challenges, what next?
Update on chronic hepatitis C treatment: current trends, new challenges, what next? Matti Maimets 12.06.2015 MMaimets15 Disclosure this presentation is sponsored by Gilead Sciences MMaimets15 MMaimets15
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationIFN-free for Genotype 1 HCV: the current landscape. Prof. Graham R Foster
IFN-free for Genotype 1 HCV: the current landscape Prof. Graham R Foster Wonderful new drugs are coming Poordad F, et al. New Engl J Med 2014; online DOI: 10.1056/NEJMoa1402869. 2 The New Drugs Two treatment
More informationHepatitis C Management and Treatment
Hepatitis C Management and Treatment Kaya Süer Near East University Faculty of Medicine Infectious Diseases and Clinical Microbiology 1 Discovery of Hepatitis C Key facts Hepatitis C: the virus can cause
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationTreatment of genotype 4 patient. with cirrhosis. Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble
Treatment of genotype 4 patient with cirrhosis Vincent LEROY Clinique Universitaire d Hépato-Gastroentérologie INSERM U823 CHU de Grenoble Clinical case 52 year-old patient Intra-venous drug user 1987-1989
More informationSelected Properties of Daclatasvir
Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and
More informationDirect Acting Antivirals for the Treatment of Hepatitis C Infection
Hepatitis C Core Curriculum, Module 2 Direct Acting Antivirals for the Treatment of Hepatitis C Infection Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP Objectives Discuss the evolution of hepatitis C treatment
More informationHALLMARK-DUAL Study. Daclatasvir + Asunaprevir in Genotype 1b. Hepatitis. Treatment-Naïve and Treatment-Experienced
Phase 3 Treatment-Naïve and Treatment-Experienced Daclatasvir + Asunaprevir in Genotype 1b HALLMARK-DUAL Study Manns M, et al. Lancet. 2014;384:1597-605. Daclatasvir + Asunaprevir for HCV GT 1b HALLMARK-DUAL:
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationSignificance of Hepatitis C. The Evolving Burden of Hepatitis C. The Bad News... The Good News... Chronic Hepatitis C Can be Cured
Journée scientifique de l'arl Yverdon, 24 mars 2011 Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois Université de Lausanne Significance of Hepatitis
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationTreatment of Chronic Hepatitis C in HIV infection
Treatment of Chronic Hepatitis C in HIV infection June 25, 211 Andrew Talal, MD, MPH Associate Professor of Medicine Associate Medical Director Center for the Study of Hepatitis C Weill Cornell Medical
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationMeta-analysis of the clinical value of oxymatrine on sustained virological response in chronic hepatitis B
482 He M, et al., 2016; 15 (4): 482-491 ORIGINAL ARTICLE July-August, Vol. 15 No. 4, 2016: 482-491 The Official Journal of the Mexican Association of Hepatology, the Latin-American Association for Study
More informationHow do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu
How do you optimize HCV Treatment for Cirrhotic Patients APASL STC Cebu Seng Gee Lim Chairman, APASL Liver Week 2013 Professor of Medicine Dept of Gastroenterology and Hepatology NUHS, Singapore Disclosures
More informationHepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More information